The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...
BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0 ...
BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its ...
Granata Bio Corporation, a biotechnology company dedicated to advancing fertility and reproductive health, and Georgetown Equity Partners (GEP) today announced the formation of a joint venture to ...
BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...
All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...
Investing.com -- BridgeBio Pharma (NASDAQ:BBIO) stock rose 15% after reporting positive Phase 3 results for its small molecule BBP-418 in the treatment of limb-girdle muscular dystrophy type 2I/R9 ...
Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant ...
InvestorsHub on MSN
BridgeBio stock soars after breakthrough Phase 3 data for muscular dystrophy treatment
BridgeBio Pharma (NASDAQ:BBIO) shares surged 15% on Monday after the company announced highly positive Phase 3 results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback